Akero Therapeutics, Inc. (AKRO)
NASDAQ: AKRO · Real-Time Price · USD
40.07
-2.65 (-6.20%)
Mar 31, 2025, 10:47 AM EDT - Market open
Akero Therapeutics Analyst Ratings
Total Analysts
9
Consensus Rating
Strong Buy
Price Target
$76.29
Upside
+90.39%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $72 → $75 | Strong Buy | Maintains | $72 → $75 | +87.17% | Mar 3, 2025 |
| UBS | UBS | Strong Buy Maintains $42 → $109 | Strong Buy | Maintains | $42 → $109 | +172.02% | Jan 31, 2025 |
| B of A Securities | B of A Securities | Hold → Strong Buy Upgrades $35 → $63 | Hold → Strong Buy | Upgrades | $35 → $63 | +57.22% | Jan 30, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $46 → $96 | Buy | Maintains | $46 → $96 | +139.58% | Jan 28, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $65 → $80 | Strong Buy | Maintains | $65 → $80 | +99.65% | Jan 28, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $56 → $73 | Strong Buy | Maintains | $56 → $73 | +82.18% | Jan 28, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $50 → $72 | Strong Buy | Maintains | $50 → $72 | +79.69% | Jan 27, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +24.78% | Jan 16, 2025 |
| Citigroup | Citigroup | Strong Buy Initiates $65 | Strong Buy | Initiates | $65 | +62.22% | Nov 18, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +24.78% | Nov 18, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +24.78% | Nov 11, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +24.78% | Sep 17, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +24.78% | Aug 12, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Jun 20, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Jun 12, 2024 |
| Wolfe Research | Wolfe Research | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Jun 11, 2024 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 10 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.